复苏性主动脉腔内球囊阻断术在非创伤性院外心脏骤停中的效果:一项跨国多中心随机对照试验
本研究为平行组、随机对照、跨国多中心试验,将在韩国和台湾的两家城市学术三级医院纳入20-80岁目击性非创伤性院外心脏骤停患者,随机分为复苏性主动脉腔内球囊阻断术联合心肺复苏组与常规心肺复苏组,主要结局为自主循环恢复,旨在评估该技术的疗效。
要点
- 纳入标准为20-80岁、目击性非创伤性院外心脏骤停患者。
- 干预组接受复苏性主动脉腔内球囊阻断术联合标准高级心血管生命支持,对照组接受基于2020年美国心脏协会指南的高级心血管生命支持。
- 主要结局为自主循环恢复,次要结局包括持续自主循环恢复、入院存活、出院存活、神经功能结局及血流动力学变化。
核心结论
- 本试验旨在评估复苏性主动脉腔内球囊阻断术联合心肺复苏相较于常规心肺复苏在非创伤性院外心脏骤停临床管理中的获益。
- 即将开展的试验可为复苏性主动脉腔内球囊阻断术作为增强冠状动脉灌注压的机械方法在院外心脏骤停复苏中的疗效提供关键证据。
研究设计与样本
- 平行组、随机对照、跨国多中心试验,将在韩国和台湾的两家城市学术三级医院开展。
- 纳入20-80岁目击性院外心脏骤停患者,需符合入选标准并从法定代理人处获取书面知情同意。
- 患者被随机分配至干预组(复苏性主动脉腔内球囊阻断术联合心肺复苏)或对照组(常规心肺复苏)。
- 干预组接受复苏性主动脉腔内球囊阻断术和标准高级心血管生命支持;对照组接受基于2020年美国心脏协会指南的高级心血管生命支持。
- 主要结局为自主循环恢复;次要结局包括持续自主循环恢复、入院存活、出院存活、神经功能结局和血流动力学变化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Out-of-hospital cardiac arrest (OHCA) is a significant public health issue worldwide and is associated with low survival rates and poor neurological outcomes. The generation of optimal coronary perfusion pressure (CPP) via high-quality chest compressions is a key factor in enhancing survival rates. However, it is often challenging to provide adequate CPP in real-world cardiopulmonary resuscitation (CPR) scenarios. Based on animal studies and human trials on improving CPP in patients with nontraumatic OHCA, resuscitative endovascular balloon occlusion of the aorta (REBOA) is a promising technique in these cases. This study aims to investigate the benefits of REBOA adjunct to CPR compared with conventional CPR for the clinical management of nontraumatic OHCA. METHODS: This is a parallel-group, randomized, controlled, multinational trial that will be conducted at two urban academic tertiary hospitals in Korea and Taiwan. Patients aged 20-80 years presenting with witnessed OHCA will be enrolled in this study. Eligible participants must fulfill the inclusion criteria, and written informed consent should be collected from their legal representatives. Patients will be randomly assigned to the intervention (REBOA-CPR) or control (conventional CPR) group. The intervention group will receive REBOA and standard advanced cardiovascular life support (ACLS). Meanwhile, the control group will receive ACLS based on the 2020 American Heart Association guidelines. The primary outcome is the return of spontaneous circulation (ROSC). The secondary outcomes include sustained ROSC, survival to admission, survival to discharge, neurological outcome, and hemodynamic changes. DISCUSSION: Our upcoming trial can provide essential evidence regarding the efficacy of REBOA, a mechanical method for enhancing CPP, in OHCA resuscitation. Our study aims to determine whether REBOA can improve treatment strategies for patients with nontraumatic OHCA based on clinical outcomes, thereby potentially providing valuable insights and guiding further advancements in this critical public health area. TRIAL REGISTRATION: ClinicalTrials.gov NCT06031623. Registered on September 9, 2023.
引用
- Kim HE, Chu SE, Jo YH, et al. Effect of resuscitative endovascular balloon occlusion of the aorta in nontraumatic out-of-hospital cardiac arrest: a multinational, multicenter, randomized, controlled trial. Trials. 2024. PMID: 38347550. doi:10.1186/s13063-024-07928-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。